Tvardi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	20.65	31.61	22.92	21.49
Short-Term Investments	20.35	-	-	22.25
Cash & Short-Term Investments	40.99	31.61	22.92	43.74
Cash Growth	78.86%	37.94%	-47.60%	-
Prepaid Expenses	2.14	0.07	3.24	0.37
Total Current Assets	43.13	31.69	26.16	44.11
Property, Plant & Equipment	0.25	0.3	0.38	0.46
Other Intangible Assets	0.35	0.39	0.45	0.51
Long-Term Deferred Charges	-	2.81	-	-
Other Long-Term Assets	0.02	0.02	0.02	0.02
Total Assets	43.75	35.2	27	45.1
Accounts Payable	2.43	2.19	1.61	2.41
Accrued Expenses	8.14	8.08	1.58	1.79
Current Portion of Leases	0.11	0.1	0.09	0.08
Total Current Liabilities	10.68	10.37	3.28	4.28
Long-Term Debt	-	30.26	-	-
Long-Term Leases	0.15	0.2	0.28	0.37
Total Liabilities	10.82	40.83	3.56	4.65
Common Stock	0.01	0.02	0.02	0.02
Additional Paid-In Capital	130.58	1.09	0.76	0.45
Retained Earnings	-97.65	-92.24	-62.84	-45.49
Comprehensive Income & Other	-0.01	-	-	-0.02
Total Common Equity	32.93	-91.13	-62.06	-45.05
Shareholders' Equity	32.93	-5.63	23.45	40.45
Total Liabilities & Equity	43.75	35.2	27	45.1
Total Debt	0.25	30.56	0.37	0.45
Net Cash (Debt)	40.74	1.05	22.55	43.29
Net Cash Growth	80.66%	-95.34%	-47.91%	-
Net Cash Per Share	5.21	0.16	3.54	6.79
Filing Date Shares Outstanding	9.38	6.4	6.38	6.37
Total Common Shares Outstanding	9.37	6.4	6.38	6.37
Working Capital	32.45	21.32	22.88	39.83
Book Value Per Share	3.51	-14.24	-9.73	-7.07
Tangible Book Value	32.57	-91.52	-62.51	-45.56
Tangible Book Value Per Share	3.48	-14.30	-9.80	-7.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q